The subject of serialisation and track-and-trace has been on the industry’s agenda for quite some time. Several of the major drug manufacturers have, in fact, made considerable inroads into implementing solutions whilst others have waited for the regulatory standards to be in force before addressing the issue. Alexander Ulbrich of Vetter outlines how, regardless of the approach taken, the industry as a whole is keenly aware of the need for serialisation and is working hard toward developing appropriate solutions.

 

Comments are closed.

%d bloggers like this: